Abstract
Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade, and promising anti-tumor activity was already observed with camrelizumab plus apatinib in chemotherapy-pretreated patients (pts) with advanced non-squamous NSCLC in the phase Ib/II study (NCT03083041). We hereby further investigated its efficacy in treatment-naive advanced NSCLC pts as in cohort 4 of this study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
